Daiichi Sankyo Collaborates with LYSA-LYSARC-CALYM for Valemetostat in Patients with R/R B-Cell Lymphoma

 Daiichi Sankyo Collaborates with LYSA-LYSARC-CALYM for Valemetostat in Patients with R/R B-Cell Lymphoma

Daiichi Sankyo Collaborates with LYSA-LYSARC-CALYM for Valemetostat in Patients with R/R B-Cell Lymphoma

Shots:

  • LYSA-LYSARC to conduct a P-II study to evaluate the safety and efficacy of valemetostat in six cohorts of patients with r/r B-cell lymphoma. The study will include ~140 patients at 22 sites in France and Belgium and is anticipated to be initiated in 2021
  • The collaboration brings together Daiichi Sankyo’s science and the multidisciplinary expertise of the LYSA, LYSARC and the CALYM research consortium to conduct clinical and translational research that will build upon the ongoing P-I study of valemetostat in patients with r/r non-Hodgkin lymphoma
  • Valemetostat (DS-3201) is an EZH1/2 dual inhibitor currently in clinical development for several hematologic cancers

Click here ­to­ read full press release/ article | Ref: Businesswire | Image: YouTube

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post